| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Adora Ndu is Director at ACAD and has filed Form 4s across 2 companies. Adora Ndu's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $695K at current prices.
The biggest single holding is ACAD (~$677K) as Director.
Adora Ndu has 9 Form 4 filings on record from June 2021 to May 2026, across 2 companies: Director at ACADIA Pharmaceuticals (ACAD), 2022–2026; Director at DBV Technologies (DBVT), 2021–2024.
The 17 reported transactions were 10 option or other derivative awards, 5 option exercises and 2 open-market purchases.
Counted by filing, the open-market trades come to 1 purchase worth about $2K and no sales.
The only open-market purchase was 1,825 shares of DBVT at an average $0.89 on February 6, 2024, about $2K. Twelve months later DBVT was down 49%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2024 | DBVT Dbv Technologies S.A. | Director | Buy | 1,825 | $0.89 | $1,624.25 | New | -24.9% | -48.7% |